Gland Pharma has informed that pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015; the trading window for dealing in securities of the Company will be closed with effect from Sunday, January 1, 2023 till 48 hours after the declaration of the Unaudited financial results of the Company for the quarter and nine months ending on December 31, 2022. The date of the Board Meeting for considering and approving the unaudited financial results of the Company for the quarter and nine months ending on December 31, 2022 will be intimated in due course.
The above information is a part of company’s filings submitted to BSE.
